arexvy rsv vaccine news

GSK, Arexvy

US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical conditions and in adults who are immunocompromised.

Hosted on MSN · 3d

GSK’s Arexvy Vaccine Shows Promise for Broader Use

GlaxoSmithKline (GB:GSK) has released an update. GSK has announced promising new data for its RSV vaccine, Arexvy, which shows potential in

Seeking Alpha on MSN · 3d

GSK reports positive data for RSV shot in younger, at-risk adults

GSK (NYSE:GSK) reported its RSV vaccine Arexvy elicited a robust immune response in recipients aged 18 to 49 years who were at increased risk of developing lower respiratory tract disease as a result of the virus due to an underlying medical condition or being immunocompromised.

Pharmabiz · 2d

New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease

New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease: London, UK Friday, October 25, 2024, 13:00 Hr

Business Insider · 2d

GSK reports preliminary data for AREXVY

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by

FiercePharma3d

GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

BioPharma Dive4d

Pfizer’s RSV vaccine cleared by FDA for use in some younger adults

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

Monthly Prescribing Reference3d

Arexvy Looks Promising for RSV Protection in Younger At-Risk and Immunocompromised Adults

Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...

BioSpace2d

CDC Reaffirm RSV Vaccination Guidelines, Declines Expanding Coverage to Younger Adults

The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for ...

The American Journal of Managed Care4d

FDA Approves Abrysvo RSV Vaccine for Adults at Increased Risk

Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.

GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

BioSpace4d

Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results